Skip to main content

Oncternal Therapeutics Value Stock - Dividend - Research Selection

Oncternal Therapeutics Inc

ISIN: US68236P1075, WKN: A2PL3P

Market price date: 28.05.2021
Market price: 5,69 USD

Oncternal Therapeutics Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 27-03-2021
Cash flow
Net operating cash flow -17.495.000
Capital Expenditures -1
Free cash flow -17.495.000
Balance sheet
Total Equity 112.951.000
Liabilities & Shareholders equity 118.809.000
Income statement
Net income -17.225.000
Eps (diluted) -0,850
Diluted shares outstanding 20.310.000
Net sales/revenue 3.375.000

Fundamental ratios calculated on: 28-05-2021

Key figures 28-05-2021
Cash flow
P/C -6,61
P/FC -6,61
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization115.563.904,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split2019-06-10,1.000000/7.000000; 2016-12-07,1.0000/10.0000; 2016-12-06,1.0000/10.0000

Description of the company

GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscles Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. In October 2012, it sold rights and related assets in the metastatic breast cancer product, Fareston, to ProStrakan Group plc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,